Takeda Pharmaceutical (TAK) Competitors

Takeda Pharmaceutical (NYSE:TAK) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, valuation and dividends.

Does the MarketBeat Community favor TAK or SNY?

Takeda Pharmaceutical received 50 more outperform votes than Sanofi when rated by MarketBeat users. However, 60.98% of users gave Sanofi an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote.

Company	Underperform	Outperform
Takeda Pharmaceutical	Outperform Votes 100 56.82%	Underperform Votes 76 43.18%
Sanofi	Outperform Votes 50 60.98%	Underperform Votes 32 39.02%

Is TAK or SNY a better dividend stock?

Takeda Pharmaceutical pays an annual dividend of $0.53 per share and has a dividend yield of 3.6%. Sanofi pays an annual dividend of $1.47 per share and has a dividend yield of 2.6%. Takeda Pharmaceutical pays out 132.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Sanofi pays out 59.0% of its earnings in the form of a dividend.

Which has more volatility & risk, TAK or SNY?

Takeda Pharmaceutical has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Is TAK or SNY more profitable?

Sanofi has a net margin of 12.77% compared to Takeda Pharmaceutical's net margin of 4.53%. Sanofi's return on equity of 25.61% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.53%	9.39%	4.53%
Sanofi	12.77%	25.61%	14.72%

Which has higher valuation & earnings, TAK or SNY?

Sanofi has lower revenue, but higher earnings than Takeda Pharmaceutical. Sanofi is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$4.58T	0.01	$994.06M	$0.40	37.10
Sanofi	$44.29B	3.24	$6.02B	$2.49	22.70

Do institutionals & insiders have more ownership in TAK or SNY?

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Does the media refer more to TAK or SNY?

In the previous week, Sanofi had 9 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 14 mentions for Sanofi and 5 mentions for Takeda Pharmaceutical. Sanofi's average media sentiment score of 0.68 beat Takeda Pharmaceutical's score of 0.41 indicating that Sanofi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sanofi	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate TAK or SNY?

Sanofi has a consensus price target of $60.00, suggesting a potential upside of 6.16%. Given Sanofi's stronger consensus rating and higher possible upside, analysts plainly believe Sanofi is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sanofi	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	3.25

Summary

Sanofi beats Takeda Pharmaceutical on 17 of the 21 factors compared between the two stocks.